Table 3 Univariate analysis of potential prognostic factors for progression-free survival (n = 35 patients) and disease-free survival (n = 35 patients) following metastasectomy of primary and hepatic metastasic lesions, respectively

Gender

 Male

24

8 (5–44)

0.324

15 (5–44)

0.346

 Female

11

27 (10–47)

20 (9–58)

Targeted therapy

 TKI+

16

47 (18–79)

0.023

58 (18–79)

0.110

 TKI–

19

19 (6–39)

19 (4–46)

ECOG

 0

29

29 (10–47)

0.015

20 (8–71)

0.132

 > 1

6

6 (2–28)

15 (1–28)

Age

 < 65 years

18

19 (8–40)

0.518

19 (5–71)

0.960

 > 65 years

17

39 (8–71)

20 (9–58)

Tumor distribution

 unilobular

28

28 (8–44)

0.772

28 (8–58)

0.981

 multilobular

7

19 (3–77)

19 (3–79)

Extrahepatic Disease

 Yes

28

27 (7–45)

0.412

19 (8–59)

0.962

 No

7

29 (4–82)

20 (4–29)

Liver metastasis Timing

 Synchronous

6

4 (2–9)

0.035

4 (2–8)

0.085

 Metachronous

29

28 (10–47)

26 (12–58)

Tumor size, cm

 < 4.5 cm

21

39 (10–71)

0.07

19 (9–42)

0.376

 > 4.5 cm

14

18 (6–29)

18 (5–35)

Resection margin

 Radical resection (R0)

30

28 (12–51)

0.001

28 (12–58)

0.014

 Irradical resection (R1/R2)

5

6 (3–10)

4 (3–9)

Number of metastases

 Solitary

22

27 (8–47)

0.653

28 (9–51)

0.967

 Multiple

13

19 (8–40)

19 (5–79)

Grading of RCC

 Low (G1/G2)

24

40 (18–71)

0.002

44 (18–71)

0.001

 High (G3/G4)

11

8 (5–19)

8 (4–19)

T-stage

 T1/T2

16

44 (12–79)

0.027

29 (15–71)

0.071

 T3/T4

19

18 (6–39)

18 (4–51)

Disease-free intervall

 < 12 months

17

28 (5–79)

0.753

28 (5–79)

0.501

 > 12 months

18

27 (10–40)

19 (9–58)